Form 4: Nuvation Bio CMO Exercises Options, Sells Shares

Nuvation Bio Inc.'s Chief Medical Officer, Liu Dongfang, exercised stock options and subsequently sold 150,000 Class A Common Stock shares for a weighted-average price of $7.8217.

Summary

• Chief Medical Officer Liu Dongfang of Nuvation Bio Inc. (NUVB) exercised 150,000 stock options at an exercise price of $2.93 per share on December 1, 2025.
• Concurrently, Liu Dongfang sold 150,000 shares of Class A Common Stock at a weighted-average price of $7.8217 per share, with prices ranging from $7.80 to $7.855.
• These transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Liu Dongfang directly owns 18,000 shares of Class A Common Stock and 165,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The transaction is a routine insider exercise and sale under a Rule 10b5-1 plan, which typically reduces the immediate market impact. While the sale itself is a reduction in insider holdings, the pre-planned nature and the profit realized make it a neutral event in terms of immediate sentiment.

Positives

• The sale price of $7.8217 is significantly higher than the exercise price of $2.93, indicating a profitable transaction for the insider.
• The transactions were executed under a Rule 10b5-1 plan, suggesting pre-planned activity rather than a reaction to immediate non-public news.

Negatives

• An insider sale, especially by a Chief Medical Officer, could be interpreted by some investors as a reduction in confidence in the company's near-term stock price appreciation, despite being pre-planned.
• The reduction in direct beneficial ownership of Class A Common Stock from 168,000 to 18,000 shares after the sale.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some may see it as a negative signal, while others recognize it as a pre-planned, routine liquidity event.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) by the Chief Medical Officer. While the sale reduces insider ownership, its execution under a Rule 10b5-1 plan suggests it is not based on new, material non-public information. Therefore, this specific filing alone does not provide sufficient new information to warrant a change in investment thesis, leading to a 'hold' recommendation. Investors should consider the company's broader financial performance and strategic outlook.

Keywords

Nuvation Bio, NUVB, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Chief Medical Officer, Liu Dongfang, Rule 10b5-1